Pharmaceutical

Sable Therapeutics and Columbia sign deal on obesity treatments

Sable Therapeutics has signed an agreement with Columbia University to develop new polycation nanomedicines aimed at treating obesity.

Aug 13, 2024 - 04:00
Sable Therapeutics and Columbia sign deal on obesity treatments
Sable Therapeutics has signed an agreement with Columbia University to develop new polycation nanomedicines aimed at treating obesity.
Read the original article

Tags:

Previous Article

Era of ADCs: Pharma companies innovate to stand out in a buzzing market

Next Article

ARS Pharmaceuticals’ anaphylaxis nasal spray gains FDA approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: House panel inches into fixing drug shortages; pharma could face legal action over improper patent listings

STAT+: Pharmalittle: House panel inches into fixing dru...

Sep 16, 2023

STAT+: ‘Shocking’ heat waves persist through August as federal officials warn of far-ranging health risks

STAT+: ‘Shocking’ heat waves persist through August as ...

Aug 7, 2023

Zai Lab and Pfizer to commercialise XACDURO in China

Zai Lab and Pfizer to commercialise XACDURO in China

Nov 23, 2024